The oral gamma secretase inhibitor is approved as a single agent for adults with progressing desmoid tumours requiring ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...

One of Ogsiveo's drugs is approved in the United States for the treatment of adults with connective tissue tumors. The headquarters is located in Stamford, Connecticut.

Ogsiveo, a drug developed by SpringWorks for patients with desmoid tumors requiring systemic treatment, could reduce the risks of a potential deal. The acquisition of SpringWorks will complement Merck ...

Six digital health technologies (DHTs) that can help with the rehabilitation of people with cardiovascular disease have been ...

On 5 February 2025, Pandora announced a new share buyback programme, cf. Company announcement no. 923. The share buyback ...

Havila Kystruten AS will publish its Q2 2025 financial report on Thursday, August 28, 2025. Bent Martini, CEO, and Aleksander Røynesdal, CFO, will present the results in an earnings call at 10:00 CET ...